drugset / Trial / NCT03597464

Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin

NCT03597464

Phase 3 Completed 216 enrolled Aurinia Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus nephritis (LN).

Timeline

Start
2019-09-29
Primary completion
2021-10-07
Completion
2021-10-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Voclosporin Other / unclassified 23.7 mg Oral

Indications